Trial Profile
A Phase III Study of SEP-190 (Eszopiclone) in Patients With Insomnia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Mar 2017
Price :
$35
*
At a glance
- Drugs Eszopiclone (Primary)
- Indications Insomnia
- Focus Adverse reactions; Registrational
- 30 Nov 2010 A Marketing Authorisation Application has been submitted in Japan based on the results from this study.
- 29 Nov 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 29 Nov 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.